

Mario Paolo Colombo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7201548/publications.pdf>

Version: 2024-02-01

296
papers

24,430
citations

8732

75
h-index

8370

147
g-index

313
all docs

313
docs citations

313
times ranked

27903
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer. <i>Cancer Discovery</i> , 2022, 12, 90-107. | 7.7 | 124 |
| 2 | Few, but Efficient: The Role of Mast Cells in Breast Cancer and Other Solid Tumors. <i>Cancer Research</i> , 2022, 82, 1439-1447. | 0.4 | 18 |
| 3 | Cancer bio-immunotherapy XVIII annual NIBIT-(Italian network for tumor biotherapy) meeting, October 15-16, 2020. <i>Cancer Immunology, Immunotherapy</i> , 2022, , 1. | 2.0 | 0 |
| 4 | Release of IFN γ by Acute Myeloid Leukemia Cells Remodels Bone Marrow Immune Microenvironment by Inducing Regulatory T Cells. <i>Clinical Cancer Research</i> , 2022, 28, 3141-3155. | 3.2 | 20 |
| 5 | Neutrophil extracellular traps arm DC vaccination against NPM-mutant myeloproliferation. <i>ELife</i> , 2022, 11, . | 2.8 | 5 |
| 6 | CIC-39Na reverses the thrombocytopenia that characterizes tubular aggregate myopathy. <i>Blood Advances</i> , 2022, 6, 4471-4484. | 2.5 | 5 |
| 7 | SCD5-dependent inhibition of SPARC secretion hampers metastatic spreading and favors host immunity in a TNBC murine model. <i>Oncogene</i> , 2022, 41, 4055-4065. | 2.6 | 10 |
| 8 | Immune-tolerance to human iPSC-derived neural progenitors xenografted into the immature cerebellum is overridden by species-specific differences in differentiation timing. <i>Scientific Reports</i> , 2021, 11, 651. | 1.6 | 6 |
| 9 | Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 622001. | 2.2 | 6 |
| 10 | The evolutionarily conserved long non-coding RNA <i>LINC00261</i> drives neuroendocrine prostate cancer proliferation and metastasis via distinct nuclear and cytoplasmic mechanisms. <i>Molecular Oncology</i> , 2021, 15, 1921-1941. | 2.1 | 22 |
| 11 | Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments. <i>Cellular Immunology</i> , 2021, 362, 104301. | 1.4 | 12 |
| 12 | Myeloid cell heterogeneity in lung cancer: implication for immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2429-2438. | 2.0 | 10 |
| 13 | CD40 Activity on Mesenchymal Cells Negatively Regulates OX40L to Maintain Bone Marrow Immune Homeostasis Under Stress Conditions. <i>Frontiers in Immunology</i> , 2021, 12, 662048. | 2.2 | 3 |
| 14 | T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Models. <i>Cancer Immunology Research</i> , 2021, 9, 825-837. | 1.6 | 6 |
| 15 | Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer. <i>Cancer Research</i> , 2021, 81, 4257-4274. | 0.4 | 11 |
| 16 | SPARC regulation of PMN clearance protects from pristane-induced lupus and rheumatoid arthritis. <i>IScience</i> , 2021, 24, 102510. | 1.9 | 5 |
| 17 | Circulating miRNAs as Novel Non-Invasive Biomarkers to Aid the Early Diagnosis of Suspicious Breast Lesions for Which Biopsy Is Recommended. <i>Cancers</i> , 2021, 13, 4028. | 1.7 | 6 |
| 18 | Macrophages Impair TLR9 Agonist Antitumor Activity through Interacting with the Anti-PD-1 Antibody Fc Domain. <i>Cancers</i> , 2021, 13, 4081. | 1.7 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. <i>Clinical Cancer Research</i> , 2021, 27, 6307-6313. | 3.2 | 8 |
| 20 | Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11-13 2019, Verona, Italy. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1. | 2.0 | 0 |
| 21 | A Spatially Resolved Dark- versus Light-Zone Microenvironment Signature Subdivides Germinal Center-Related Aggressive B Cell Lymphomas. <i>IScience</i> , 2020, 23, 101562. | 1.9 | 27 |
| 22 | Immunometabolic Status of COVID-19 Cancer Patients. <i>Physiological Reviews</i> , 2020, 100, 1839-1850. | 13.1 | 20 |
| 23 | Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces. <i>EBioMedicine</i> , 2020, 61, 103055. | 2.7 | 21 |
| 24 | T Cell Costimulation Blockade Blunts Age-Related Heart Failure. <i>Circulation Research</i> , 2020, 127, 1115-1117. | 2.0 | 19 |
| 25 | Response of a comprehensive cancer center to the COVID-19 pandemic: the experience of the Fondazione IRCCS-Istituto Nazionale dei Tumori di Milano. <i>Tumori</i> , 2020, 106, 193-202. | 0.6 | 32 |
| 26 | Infiltrating Mast Cell-Mediated Stimulation of Estrogen Receptor Activity in Breast Cancer Cells Promotes the Luminal Phenotype. <i>Cancer Research</i> , 2020, 80, 2311-2324. | 0.4 | 28 |
| 27 | Tumor-Derived Prostaglandin E2 Promotes p50 NF- κ B-Dependent Differentiation of Monocytic MDSCs. <i>Cancer Research</i> , 2020, 80, 2874-2888. | 0.4 | 81 |
| 28 | Circulating and tumor-associated neutrophil subtypes discriminate hyperprogressive disease (HPD) from conventional progression (PD) upon immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients (pts) and in vivo models.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9547-9547. | 0.8 | 2 |
| 29 | Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study. <i>PLoS ONE</i> , 2019, 14, e0220644. | 1.1 | 6 |
| 30 | Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 815-828. | 2.1 | 11 |
| 31 | SPARC Is a New Myeloid-Derived Suppressor Cell Marker Licensing Suppressive Activities. <i>Frontiers in Immunology</i> , 2019, 10, 1369. | 2.2 | 44 |
| 32 | Prognostic role of CD73 in metastatic non small cell lung cancer according to the presence of driver alterations. <i>Annals of Oncology</i> , 2019, 30, v800. | 0.6 | 0 |
| 33 | Single-Cell Sequencing of Mouse Heart Immune Infiltrate in Pressure Overload-Driven Heart Failure Reveals Extent of Immune Activation. <i>Circulation</i> , 2019, 140, 2089-2107. | 1.6 | 212 |
| 34 | The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment. <i>Oncogene</i> , 2019, 38, 3636-3650. | 2.6 | 144 |
| 35 | Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy. <i>Cancers</i> , 2019, 11, 624. | 1.7 | 32 |
| 36 | IL-10-producing B cells are characterized by a specific methylation signature. <i>European Journal of Immunology</i> , 2019, 49, 1213-1225. | 1.6 | 19 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | DNA threads released by activated CD4 ⁺ T lymphocytes provide autocrine costimulation. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 8985-8994. | 3.3 | 33 |
| 38 | When Failure Is Worse Than Giving Up: The Case of CTL. Cancer Research, 2019, 79, 1753-1755. | 0.4 | 0 |
| 39 | Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. Lung Cancer, 2019, 132, 72-78. | 0.9 | 54 |
| 40 | Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open, 2019, 4, e000457. | 2.0 | 151 |
| 41 | Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. Cancer Treatment Reviews, 2019, 75, 39-51. | 3.4 | 124 |
| 42 | Frontline Science: Mast cells regulate neutrophil homeostasis by influencing macrophage clearance activity. Journal of Leukocyte Biology, 2019, 105, 633-644. | 1.5 | 7 |
| 43 | Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells. Cancer Research, 2019, 79, 1938-1951. | 0.4 | 58 |
| 44 | Transcriptional profiles and stromal changes reveal bone marrow adaptation to early breast cancer in association with deregulated circulating microRNAs. Cancer Research, 2019, 80, canres.1425.2019. | 0.4 | 13 |
| 45 | A luminal EF-hand mutation in STIM1 in mice causes the clinical hallmarks of tubular aggregate myopathy. DMM Disease Models and Mechanisms, 2019, 13, . | 1.2 | 16 |
| 46 | OA14.06 Hyperprogressive Disease in Advanced Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. Journal of Thoracic Oncology, 2019, 14, S245. | 0.5 | 1 |
| 47 | Is GPNMB the Achilles' Heel of Mo-MDSC While Marking Their Suppressive Activity?. Clinical Cancer Research, 2019, 25, 453-454. | 3.2 | 6 |
| 48 | Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. Clinical Cancer Research, 2019, 25, 989-999. | 3.2 | 315 |
| 49 | Exploiting Fasting-mimicking Diet and METformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. Clinical Lung Cancer, 2019, 20, e413-e417. | 1.1 | 27 |
| 50 | Abstract SY35-02: Bone marrow remodeling in response to distant tumor starts early in transformation. , 2019, , . | | 0 |
| 51 | Mechanisms of Tolerance Induction through T Regulatory Cells during Chemotherapy-Mediated Immunogenic Cell Death in Acute Myeloid Leukemia. Blood, 2019, 134, 2332-2332. | 0.6 | 0 |
| 52 | Interferon-Î³-Dependent Inflammatory Signature in Acute Myeloid Leukemia Cells Is Able to Shape Stromal and Immune Bone Marrow Microenvironment. Blood, 2019, 134, 1212-1212. | 0.6 | 2 |
| 53 | Abstract SY35-02: Bone marrow remodeling in response to distant tumor starts early in transformation. , 2019, , . | | 0 |
| 54 | Cross-Talk between Myeloid-Derived Suppressor Cells and Mast Cells Mediates Tumor-Specific Immunosuppression in Prostate Cancer. Cancer Immunology Research, 2018, 6, 552-565. | 1.6 | 44 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | cIAP1 regulates the EGFR/Snai2 axis in triple-negative breast cancer cells. <i>Cell Death and Differentiation</i> , 2018, 25, 2147-2164. | 5.0 | 15 |
| 56 | Mast cells, basophils and eosinophils: From allergy to cancer. <i>Seminars in Immunology</i> , 2018, 35, 29-34. | 2.7 | 66 |
| 57 | Separation of Dual Oxidase 2 and Lactoperoxidase Expression in Intestinal Crypts and Species Differences May Limit Hydrogen Peroxide Scavenging During Mucosal Healing in Mice and Humans. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 136-148. | 0.9 | 11 |
| 58 | OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis. <i>Oncolmmunology</i> , 2018, 7, e1465164. | 2.1 | 3 |
| 59 | Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity. <i>Cancer Research</i> , 2018, 78, 5729-5730. | 0.4 | 11 |
| 60 | Diagnostic role of circulating extracellular matrix-related proteins in non-small cell lung cancer. <i>BMC Cancer</i> , 2018, 18, 899. | 1.1 | 45 |
| 61 | Role of PD-L1 expression in triple-negative breast cancer stem cells.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12081-12081. | 0.8 | 1 |
| 62 | Abstract A24: Bone marrow hematopoietic adaptation as a sensor of early, pre-invasive, epithelial malignancy. , 2018, , . | | 0 |
| 63 | Abstract 2141: Stromal SPARC deficiency skews prostate cancer toward neuroendocrine differentiation. , 2018, , . | | 0 |
| 64 | Up-Regulation of Immune Tolerance Genes in Leukemic Mesenchymal Stromal Cells Is Induced By Acute Myeloid Leukemia Cells through an IFN-Gamma-Dependent Inflammatory Signaling. <i>Blood</i> , 2018, 132, 2579-2579. | 0.6 | 0 |
| 65 | Matricellular proteins tune myeloid-derived suppressor cell recruitment and function in breast cancer. <i>Journal of Leukocyte Biology</i> , 2017, 102, 287-292. | 1.5 | 20 |
| 66 | Common extracellular matrix regulation of myeloid cell activity in the bone marrow and tumor microenvironments. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1059-1067. | 2.0 | 36 |
| 67 | Sarcoma Eradication by Doxorubicin and Targeted TNF Relies upon CD8+ T-cell Recognition of a Retroviral Antigen. <i>Cancer Research</i> , 2017, 77, 3644-3654. | 0.4 | 55 |
| 68 | Rheostatic Functions of Mast Cells in the Control of Innate and Adaptive Immune Responses. <i>Trends in Immunology</i> , 2017, 38, 648-656. | 2.9 | 66 |
| 69 | Reciprocal influence of B cells and tumor macro and microenvironments in the <i>Apc^{Min/+}</i> model of colorectal cancer. <i>Oncolmmunology</i> , 2017, 6, e1336593. | 2.1 | 8 |
| 70 | Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling. <i>Cancer Research</i> , 2017, 77, 3685-3699. | 0.4 | 27 |
| 71 | Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2017, 23, 5149-5161. | 3.2 | 59 |
| 72 | Imatinib Spares cKit-Expressing Prostate Neuroendocrine Tumors, whereas Kills Seminal Vesicle Epithelial Stromal Tumors by Targeting PDGFR- β . <i>Molecular Cancer Therapeutics</i> , 2017, 16, 365-375. | 1.9 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?. <i>Clinical Cancer Research</i> , 2017, 23, 5999-6001. | 3.2 | 10 |
| 74 | The good and bad of targeting cancer-associated extracellular matrix. <i>Current Opinion in Pharmacology</i> , 2017, 35, 75-82. | 1.7 | 23 |
| 75 | Antibody-mediated blockade of JMJD6 interaction with collagen I exerts antifibrotic and antimetastatic activities. <i>FASEB Journal</i> , 2017, 31, 5356-5370. | 0.2 | 10 |
| 76 | Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT). <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 1-3. | 3.2 | 1 |
| 77 | ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells. <i>Frontiers in Immunology</i> , 2017, 8, 1918. | 2.2 | 72 |
| 78 | Neoadjuvant eribulin following anthracycline and taxane in triple negative breast cancer (HOPE): A multicenter, two stage, phase II trial. <i>Annals of Oncology</i> , 2017, 28, v50. | 0.6 | 0 |
| 79 | Mesenchymal Transition of High-Grade Breast Carcinomas Depends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity. <i>Cell Reports</i> , 2016, 17, 233-248. | 2.9 | 84 |
| 80 | Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. <i>Nature Communications</i> , 2016, 7, 12150. | 5.8 | 2,076 |
| 81 | Healthy and tumoral tissue resistivity in wild-type and sparc ^{-/-} animal models. <i>Medical and Biological Engineering and Computing</i> , 2016, 54, 1949-1957. | 1.6 | 7 |
| 82 | CD99 regulates neural differentiation of Ewing sarcoma cells through miR-34a-Notch-mediated control of NF- κ B signaling. <i>Oncogene</i> , 2016, 35, 3944-3954. | 2.6 | 51 |
| 83 | TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Armed Exosomes Deliver Proapoptotic Signals to Tumor Site. <i>Clinical Cancer Research</i> , 2016, 22, 3499-3512. | 3.2 | 158 |
| 84 | CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling. <i>Oncotarget</i> , 2016, 7, 79925-79942. | 0.8 | 40 |
| 85 | Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers. <i>Oncotarget</i> , 2016, 7, 3905-3920. | 0.8 | 9 |
| 86 | Abstract B157: OX40 expression in tumor-associated Tregs as a potential prognostic biomarker and immunotherapeutic target in ovarian cancer. , 2016, , . | | 0 |
| 87 | Chemotherapy-Dependent ATP Release from Leukemia Dying Cells Induces Indoleamine 2,3-Dioxygenase 1 in Dendritic Cells. <i>Blood</i> , 2016, 128, 3711-3711. | 0.6 | 0 |
| 88 | Consensus nomenclature for CD8 ⁺ T cell phenotypes in cancer. <i>Oncolmmunology</i> , 2015, 4, e998538. | 2.1 | 119 |
| 89 | Mast Cells Infiltrating Inflamed or Transformed Gut Alternatively Sustain Mucosal Healing or Tumor Growth. <i>Cancer Research</i> , 2015, 75, 3760-3770. | 0.4 | 27 |
| 90 | Regulated Expression of miR-155 is Required for iNKT Cell Development. <i>Frontiers in Immunology</i> , 2015, 6, 140. | 2.2 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | The ins and outs of osteopontin. <i>Oncolmmunology</i> , 2015, 4, e978711. | 2.1 | 3 |
| 92 | SOCS2 Controls Proliferation and Stemness of Hematopoietic Cells under Stress Conditions and Its Deregulation Marks Unfavorable Acute Leukemias. <i>Cancer Research</i> , 2015, 75, 2387-2399. | 0.4 | 39 |
| 93 | CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin. <i>Clinical Cancer Research</i> , 2015, 21, 146-156. | 3.2 | 42 |
| 94 | SCD5-induced oleic acid production reduces melanoma malignancy by intracellular retention of SPARC and cathepsin B. <i>Journal of Pathology</i> , 2015, 236, 315-325. | 2.1 | 34 |
| 95 | RORC1 Regulates Tumor-Promoting "Emergency" Granulo-Monocytopenesis. <i>Cancer Cell</i> , 2015, 28, 253-269. | 7.7 | 154 |
| 96 | The Role of Mast Cells in Molding the Tumor Microenvironment. <i>Cancer Microenvironment</i> , 2015, 8, 167-176. | 3.1 | 62 |
| 97 | Mast Cells Boost Myeloid-Derived Suppressor Cell Activity and Contribute to the Development of Tumor-Favoring Microenvironment. <i>Cancer Immunology Research</i> , 2015, 3, 85-95. | 1.6 | 59 |
| 98 | OX40 expression in tumor-associated Tregs as a potential prognostic biomarker and immunotherapeutic target in ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16576-e16576. | 0.8 | 0 |
| 99 | Abstract 4054: Mast cells contribute to T cell tolerance against prostate cancer- associated antigens favoring tumor growth. , 2015, , . | | 0 |
| 100 | MEF2C and SOCS2 in stemness regulation. <i>Oncoscience</i> , 2015, 2, 936-937. | 0.9 | 2 |
| 101 | The Induction of Inhibitory Pathways in Dendritic Cells May Hamper the Efficient Activation of Anti-Leukemia T Cells within Chemotherapy-Induced Immunogenic Cell Death. <i>Blood</i> , 2015, 126, 1019-1019. | 0.6 | 0 |
| 102 | Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508. | 0.8 | 395 |
| 103 | Stromal niche communalities underscore the contribution of the matricellular protein SPARC to B-cell development and lymphoid malignancies. <i>Oncolmmunology</i> , 2014, 3, e28989. | 2.1 | 34 |
| 104 | Defective Stromal Remodeling and Neutrophil Extracellular Traps in Lymphoid Tissues Favor the Transition from Autoimmunity to Lymphoma. <i>Cancer Discovery</i> , 2014, 4, 110-129. | 7.7 | 100 |
| 105 | Suppression of Invasion and Metastasis of Triple-Negative Breast Cancer Lines by Pharmacological or Genetic Inhibition of Slug Activity. <i>Neoplasia</i> , 2014, 16, 1047-1058. | 2.3 | 78 |
| 106 | CD99 Drives Terminal Differentiation of Osteosarcoma Cells by Acting as a Spatial Regulator of ERK 1/2. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1295-1309. | 3.1 | 37 |
| 107 | Editors' Viewpoint"Response. <i>Cancer Research</i> , 2014, 74, 635-635. | 0.4 | 0 |
| 108 | Expression levels of insulin receptor substrate-1 modulate the osteoblastic differentiation of mesenchymal stem cells and osteosarcoma cells. <i>Growth Factors</i> , 2014, 32, 41-52. | 0.5 | 18 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Osteopontin Shapes Immunosuppression in the Metastatic Niche. <i>Cancer Research</i> , 2014, 74, 4706-4719. | 0.4 | 110 |
| 110 | Mast Cells Control the Expansion and Differentiation of IL-10-Competent B Cells. <i>Journal of Immunology</i> , 2014, 193, 4568-4579. | 0.4 | 33 |
| 111 | Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma. <i>Blood</i> , 2014, 123, 1836-1849. | 0.6 | 37 |
| 112 | Mast Cells and Immune Response in Cancer. , 2014, , 77-98. | | 0 |
| 113 | The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR-221&222-FOS pathway. <i>International Journal of Cancer</i> , 2013, 133, 879-892. | 2.3 | 55 |
| 114 | IL-15 cis Presentation Is Required for Optimal NK Cell Activation in Lipopolysaccharide-Mediated Inflammatory Conditions. <i>Cell Reports</i> , 2013, 4, 1235-1249. | 2.9 | 66 |
| 115 | Ultrasound-guided intra-tumor injection of combined immunotherapy cures mice from orthotopic prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1811-1819. | 2.0 | 3 |
| 116 | Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases. <i>International Journal of Cancer</i> , 2013, 133, 383-393. | 2.3 | 20 |
| 117 | Inhibiting Interactions of Lysine Demethylase LSD1 with Snail/Slug Blocks Cancer Cell Invasion. <i>Cancer Research</i> , 2013, 73, 235-245. | 0.4 | 117 |
| 118 | Convergences and Divergences of Thymus- and Peripherally Derived Regulatory T Cells in Cancer. <i>Frontiers in Immunology</i> , 2013, 4, 247. | 2.2 | 25 |
| 119 | Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity. <i>Cell Death and Disease</i> , 2013, 4, e920-e920. | 2.7 | 41 |
| 120 | Neoplastic and Stromal Cells Contribute to an Extracellular Matrix Gene Expression Profile Defining a Breast Cancer Subtype Likely to Progress. <i>PLoS ONE</i> , 2013, 8, e56761. | 1.1 | 41 |
| 121 | Abstract A102: Osteopontin produced by myeloid cells determines the outcome of breast cancer metastases. , 2013, , . | | 3 |
| 122 | Liver Follicular Helper T-Cells Predict the Achievement of Virological Response following Interferon-Based Treatment in HCV-Infected Patients. <i>Antiviral Therapy</i> , 2012, 17, 111-118. | 0.6 | 12 |
| 123 | Mast Cells in the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. <i>International Journal of Molecular Sciences</i> , 2012, 13, 15107-15125. | 1.8 | 33 |
| 124 | The Dark Side of Mast Cell-Targeted Therapy in Prostate Cancer. <i>Cancer Research</i> , 2012, 72, 831-835. | 0.4 | 52 |
| 125 | The Aryl Hydrocarbon Receptor Modulates Acute and Late Mast Cell Responses. <i>Journal of Immunology</i> , 2012, 189, 120-127. | 0.4 | 70 |
| 126 | Microenvironment-Centred Dynamics in Aggressive B-Cell Lymphomas. <i>Advances in Hematology</i> , 2012, 2012, 1-12. | 0.6 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 127 | Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion. <i>Blood</i> , 2012, 120, 3541-3554. | 0.6 | 44 |
| 128 | Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. <i>Blood</i> , 2012, 120, 3007-3018. | 0.6 | 350 |
| 129 | Modulation of Fc μ RI-dependent mast cell response by OX40L via Fyn, PI3K, and RhoA. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 751-760.e2. | 1.5 | 23 |
| 130 | SPARC Oppositely Regulates Inflammation and Fibrosis in Bleomycin-Induced Lung Damage. <i>American Journal of Pathology</i> , 2011, 179, 3000-3010. | 1.9 | 62 |
| 131 | The matricellular protein SPARC supports follicular dendritic cell networking toward Th17 responses. <i>Journal of Autoimmunity</i> , 2011, 37, 300-310. | 3.0 | 29 |
| 132 | Constitutive activation of the ETS α 1 α 22 circuitry in metastatic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 953-965. | 1.5 | 36 |
| 133 | Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors. <i>Oncogene</i> , 2011, 30, 757-769. | 2.6 | 70 |
| 134 | Exacerbated experimental autoimmune encephalomyelitis in mast-cell-deficient Kit W -sh/ W -sh mice. <i>Laboratory Investigation</i> , 2011, 91, 627-641. | 1.7 | 61 |
| 135 | Intratumor OX40 stimulation inhibits IRF1 expression and IL α 10 production by Treg cells while enhancing CD40L expression by effector memory T cells. <i>European Journal of Immunology</i> , 2011, 41, 3615-3626. | 1.6 | 39 |
| 136 | The bone marrow stroma in hematological neoplasms α a guilty bystander. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 456-466. | 12.5 | 42 |
| 137 | Mast Cell Targeting Hampers Prostate Adenocarcinoma Development but Promotes the Occurrence of Highly Malignant Neuroendocrine Cancers. <i>Cancer Research</i> , 2011, 71, 5987-5997. | 0.4 | 124 |
| 138 | Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis. <i>Cancer and Metastasis Reviews</i> , 2010, 29, 295-307. | 2.7 | 207 |
| 139 | Peripheral regulatory T cells and serum transforming growth factor- β 2: Relationship with clinical response to infliximab in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1891-1897. | 0.9 | 40 |
| 140 | A non α redundant role for OX40 in the competitive fitness of Treg in response to IL α 2. <i>European Journal of Immunology</i> , 2010, 40, 2902-2913. | 1.6 | 62 |
| 141 | Oncogene-Driven Intrinsic Inflammation Induces Leukocyte Production of Tumor Necrosis Factor That Critically Contributes to Mammary Carcinogenesis. <i>Cancer Research</i> , 2010, 70, 7764-7775. | 0.4 | 31 |
| 142 | Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated with Autologous Tumor Cells Experiencing Immunogenic Death. <i>Cancer Research</i> , 2010, 70, 9062-9072. | 0.4 | 126 |
| 143 | Xg Expression in Ewing's Sarcoma Is of Prognostic Value and Contributes to Tumor Invasiveness. <i>Cancer Research</i> , 2010, 70, 3730-3738. | 0.4 | 21 |
| 144 | Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. <i>Journal of Experimental Medicine</i> , 2010, 207, 2931-2942. | 4.2 | 175 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Mast Cells and Th17 Cells Contribute to the Lymphoma-Associated Pro-Inflammatory Microenvironment of Angioimmunoblastic T-Cell Lymphoma. <i>American Journal of Pathology</i> , 2010, 177, 792-802. | 1.9 | 82 |
| 146 | CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. <i>Journal of Clinical Investigation</i> , 2010, 120, 668-680. | 3.9 | 150 |
| 147 | Polyps Wrap Mast Cells and Treg within Tumorigenic Tentacles. <i>Cancer Research</i> , 2009, 69, 5619-5622. | 0.4 | 17 |
| 148 | An unusual BRCA2 allele carrying two splice site mutations. <i>Annals of Oncology</i> , 2009, 20, 1143-1144. | 0.6 | 8 |
| 149 | Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation. <i>Blood</i> , 2009, 114, 2639-2648. | 0.6 | 184 |
| 150 | CD4+CD25+ Regulatory T Cells Suppress Mast Cell Degranulation and Allergic Responses through OX40-OX40L Interaction. <i>Immunity</i> , 2008, 29, 771-781. | 6.6 | 333 |
| 151 | Matricellular proteins at the crossroad of inflammation and cancer. <i>Cancer Letters</i> , 2008, 267, 245-253. | 3.2 | 33 |
| 152 | The Promyelocytic Leukemia Zinc Finger- μ MicroRNA-221/-222 Pathway Controls Melanoma Progression through Multiple Oncogenic Mechanisms. <i>Cancer Research</i> , 2008, 68, 2745-2754. | 0.4 | 357 |
| 153 | Contrasting roles of SPARC-related granuloma in bacterial containment and in the induction of anti- <i>Salmonella typhimurium</i> immunity. <i>Journal of Experimental Medicine</i> , 2008, 205, 657-667. | 4.2 | 22 |
| 154 | OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. <i>Journal of Experimental Medicine</i> , 2008, 205, 1505-1505. | 4.2 | 2 |
| 155 | Macrophage-Derived SPARC Bridges Tumor Cell-Extracellular Matrix Interactions toward Metastasis. <i>Cancer Research</i> , 2008, 68, 9050-9059. | 0.4 | 174 |
| 156 | OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. <i>Journal of Experimental Medicine</i> , 2008, 205, 825-839. | 4.2 | 369 |
| 157 | Contrasting roles of SPARC-related granuloma in bacterial containment and in the induction of anti- <i>Salmonella typhimurium</i> immunity. <i>Journal of Cell Biology</i> , 2008, 180, i17-i17. | 2.3 | 0 |
| 158 | The Terminology Issue for Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , 2007, 67, 425-425. | 0.4 | 649 |
| 159 | Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. <i>Annals of Oncology</i> , 2007, 18, 226-232. | 0.6 | 252 |
| 160 | Caveolin-1 Reduces Osteosarcoma Metastases by Inhibiting c-Src Activity and Met Signaling. <i>Cancer Research</i> , 2007, 67, 7675-7685. | 0.4 | 81 |
| 161 | Amino-Biphosphonate- μ Mediated MMP-9 Inhibition Breaks the Tumor-Bone Marrow Axis Responsible for Myeloid-Derived Suppressor Cell Expansion and Macrophage Infiltration in Tumor Stroma. <i>Cancer Research</i> , 2007, 67, 11438-11446. | 0.4 | 310 |
| 162 | Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25 μ into CD25+ T regulatory cells. <i>Blood</i> , 2007, 109, 2871-2877. | 0.6 | 357 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 163 | Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2007, 7, 880-887. | 12.8 | 379 |
| 164 | Nucleofection Is an Efficient Nonviral Transfection Technique for Human Bone Marrow-Derived Mesenchymal Stem Cells. <i>Stem Cells</i> , 2006, 24, 454-461. | 1.4 | 123 |
| 165 | Triggering CD40 on endothelial cells contributes to tumor growth. <i>Journal of Experimental Medicine</i> , 2006, 203, 2441-2450. | 4.2 | 73 |
| 166 | CD99 Acts as an Oncosuppressor in Osteosarcoma. <i>Molecular Biology of the Cell</i> , 2006, 17, 1910-1921. | 0.9 | 60 |
| 167 | CD25+ Regulatory T Cell Depletion Augments Immunotherapy of Micrometastases by an IL-21-Secreting Cellular Vaccine. <i>Journal of Immunology</i> , 2006, 176, 1750-1758. | 0.4 | 96 |
| 168 | Low Surface Expression of B7-1 (CD80) Is an Immunoescape Mechanism of Colon Carcinoma. <i>Cancer Research</i> , 2006, 66, 2442-2450. | 0.4 | 129 |
| 169 | Tumor-Induced Expansion of Regulatory T Cells by Conversion of CD4+CD25 ^{hi} Lymphocytes Is Thymus and Proliferation Independent. <i>Cancer Research</i> , 2006, 66, 4488-4495. | 0.4 | 230 |
| 170 | p50 Nuclear Factor- κ B Overexpression in Tumor-Associated Macrophages Inhibits M1 Inflammatory Responses and Antitumor Resistance. <i>Cancer Research</i> , 2006, 66, 11432-11440. | 0.4 | 397 |
| 171 | Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. <i>Journal of Clinical Investigation</i> , 2006, 116, 2777-2790. | 3.9 | 723 |
| 172 | Triggering of OX40 (CD134) on CD4+CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. <i>Blood</i> , 2005, 105, 2845-2851. | 0.6 | 358 |
| 173 | Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. <i>Blood</i> , 2005, 106, 3846-3853. | 0.6 | 110 |
| 174 | In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. <i>Oncogene</i> , 2005, 24, 4349-4361. | 2.6 | 90 |
| 175 | Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. <i>Experimental Hematology</i> , 2005, 33, 1521-1530. | 0.2 | 44 |
| 176 | CD40/CD40L interaction regulates CD4+CD25+ T reg homeostasis through dendritic cell-produced IL-2. <i>European Journal of Immunology</i> , 2005, 35, 557-567. | 1.6 | 108 |
| 177 | Chaperon and Adjuvant Activity of hsp70: Different Natural Killer Requirement for Cross-Priming of Chaperoned and Bystander Antigens. <i>Cancer Research</i> , 2005, 65, 7942-7949. | 0.4 | 43 |
| 178 | Targeting Myelomonocytic Cells to Revert Inflammation-Dependent Cancer Promotion: Figure 1.. <i>Cancer Research</i> , 2005, 65, 9113-9116. | 0.4 | 88 |
| 179 | Redirecting <i>In vivo</i> Elicited Tumor Infiltrating Macrophages and Dendritic Cells towards Tumor Rejection. <i>Cancer Research</i> , 2005, 65, 3437-3446. | 0.4 | 498 |
| 180 | Accelerated dendritic-cell migration and T-cell priming in SPARC-deficient mice. <i>Journal of Cell Science</i> , 2005, 118, 3685-3694. | 1.2 | 60 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Reconstitution of Human Telomerase Reverse Transcriptase Expression Rescues Colorectal Carcinoma Cells from In vitro Senescence: Evidence against Immortality as a Constitutive Trait of Tumor Cells. <i>Cancer Research</i> , 2005, 65, 2321-2329. | 0.4 | 26 |
| 182 | Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 4185-4190. | 3.3 | 271 |
| 183 | Cancer Immunotherapy Based on Killing of Salmonella-Infected Tumor Cells. <i>Cancer Research</i> , 2005, 65, 3920-3927. | 0.4 | 157 |
| 184 | IL-21 Induces Tumor Rejection by Specific CTL and IFN- γ -Dependent CXC Chemokines in Syngeneic Mice. <i>Journal of Immunology</i> , 2004, 172, 1540-1547. | 0.4 | 146 |
| 185 | Intralesional Injection of Adenovirus Encoding CC Chemokine Ligand 16 Inhibits Mammary Tumor Growth and Prevents Metastatic-Induced Death after Surgical Removal of the Treated Primary Tumor. <i>Journal of Immunology</i> , 2004, 172, 4026-4036. | 0.4 | 38 |
| 186 | Role of PLZF in melanoma progression. <i>Oncogene</i> , 2004, 23, 4567-4576. | 2.6 | 62 |
| 187 | Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. <i>Oncogene</i> , 2004, 23, 5664-5674. | 2.6 | 108 |
| 188 | Angiopoietin decoy secreted at tumor site impairs tumor growth and metastases by inducing local inflammation and altering neoangiogenesis. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 600-608. | 2.0 | 22 |
| 189 | CpG-Oligodeoxynucleotides activate tyrosinase-related protein 2-specific T lymphocytes but do not lead to a protective tumor-specific memory response. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 697-704. | 2.0 | 6 |
| 190 | Enhanced Efficacy of Tumor Cell Vaccines Transfected with Secretable hsp70. <i>Cancer Research</i> , 2004, 64, 1502-1508. | 0.4 | 60 |
| 191 | HOXB7 expression is regulated by the transcription factors NF-Y, YY1, Sp1 and USF-1. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 2003, 1626, 1-9. | 2.4 | 18 |
| 192 | Leukocyte, Rather than Tumor-produced SPARC, Determines Stroma and Collagen Type IV Deposition in Mammary Carcinoma. <i>Journal of Experimental Medicine</i> , 2003, 198, 1475-1485. | 4.2 | 124 |
| 193 | OX40 Ligand-Transduced Tumor Cell Vaccine Synergizes with GM-CSF and Requires CD40-Apc Signaling to Boost the Host T Cell Antitumor Response. <i>Journal of Immunology</i> , 2003, 170, 99-106. | 0.4 | 67 |
| 194 | Lipopolysaccharide or Whole Bacteria Block the Conversion of Inflammatory Monocytes into Dendritic Cells In Vivo. <i>Journal of Experimental Medicine</i> , 2003, 198, 1253-1263. | 4.2 | 107 |
| 195 | IL-4-Induced Arginase 1 Suppresses Alloreactive T Cells in Tumor-Bearing Mice. <i>Journal of Immunology</i> , 2003, 170, 270-278. | 0.4 | 445 |
| 196 | Autologous and MHC class II-negative allogeneic tumor cells secreting IL-12 together cure disseminated A20 lymphoma. <i>Blood</i> , 2003, 101, 568-575. | 0.6 | 24 |
| 197 | Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. <i>Blood</i> , 2003, 102, 2138-2145. | 0.6 | 260 |
| 198 | Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. <i>Journal of Clinical Investigation</i> , 2003, 111, 1161-1170. | 3.9 | 27 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 199 | Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. <i>Journal of Clinical Investigation</i> , 2003, 111, 1161-1170. | 3.9 | 105 |
| 200 | Absence of the CD1 Molecule Up-Regulates Antitumor Activity Induced by CpG Oligodeoxynucleotides in Mice. <i>Journal of Immunology</i> , 2002, 169, 151-158. | 0.4 | 34 |
| 201 | Reversal of Tumor-induced Dendritic Cell Paralysis by CpG Immunostimulatory Oligonucleotide and Anti-Interleukin 10 Receptor Antibody. <i>Journal of Experimental Medicine</i> , 2002, 196, 541-549. | 4.2 | 322 |
| 202 | Interleukin-12 in anti-tumor immunity and immunotherapy. <i>Cytokine and Growth Factor Reviews</i> , 2002, 13, 155-168. | 3.2 | 627 |
| 203 | Introduction: Cytokines and Cancer. <i>Cytokine and Growth Factor Reviews</i> , 2002, 13, 93-94. | 3.2 | 4 |
| 204 | Application of multicolor fluorescence in situ hybridization analysis for detection of cross-contamination and in vitro progression in commonly used murine tumor cell lines. <i>Cancer Genetics and Cytogenetics</i> , 2002, 139, 126-132. | 1.0 | 7 |
| 205 | IFN- β -independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice. <i>European Journal of Immunology</i> , 2002, 32, 1914. | 1.6 | 42 |
| 206 | Vaccination of Stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. <i>Cancer Immunology, Immunotherapy</i> , 2002, 51, 9-14. | 2.0 | 38 |
| 207 | Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15. <i>Cancer Research</i> , 2002, 62, 4390-7. | 0.4 | 25 |
| 208 | The intriguing role of polymorphonuclear neutrophils in antitumor reactions. <i>Blood</i> , 2001, 97, 339-345. | 0.6 | 375 |
| 209 | Simultaneous transduction of B7-1 and IL-2 genes into human melanoma cells to be used as vaccine: enhancement of stimulatory activity for autologous and allogeneic lymphocytes. <i>Cancer Immunology, Immunotherapy</i> , 2001, 50, 199-211. | 2.0 | 16 |
| 210 | Different requirements for β -galactosylceramide and recombinant IL-12 antitumor activity in the treatment of C-26 colon carcinoma hepatic metastases. <i>European Journal of Immunology</i> , 2001, 31, 3101-3110. | 1.6 | 19 |
| 211 | IL-12 Inhibition of Endothelial Cell Functions and Angiogenesis Depends on Lymphocyte-Endothelial Cell Cross-Talk. <i>Journal of Immunology</i> , 2001, 166, 3890-3899. | 0.4 | 157 |
| 212 | Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice. <i>Journal of Experimental Medicine</i> , 2001, 194, 1195-1206. | 4.2 | 218 |
| 213 | Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats. <i>Journal of Neurosurgery</i> , 2000, 92, 419-427. | 0.9 | 60 |
| 214 | Overexpression of protectin (CD59) down-modulates the susceptibility of human melanoma cells to homologous complement. <i>Journal of Cellular Physiology</i> , 2000, 185, 317-323. | 2.0 | 26 |
| 215 | Modulation of host immune responses stimulated by <i>Salmonella</i> vaccine carrier strains by using different promoters to drive the expression of the recombinant antigen. <i>European Journal of Immunology</i> , 2000, 30, 768-777. | 1.6 | 28 |
| 216 | Wild-type HFE protein normalizes transferrin iron accumulation in macrophages from subjects with hereditary hemochromatosis. <i>Blood</i> , 2000, 96, 1125-1129. | 0.6 | 140 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 217 | DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice. <i>Journal of Immunology</i> , 2000, 165, 5133-5142. | 0.4 | 326 |
| 218 | Immunizing Potential of Cytokine-Transduced Tumor Cells. , 2000, 35, 3-26. | | 0 |
| 219 | Wild-type HFE protein normalizes transferrin iron accumulation in macrophages from subjects with hereditary hemochromatosis. <i>Blood</i> , 2000, 96, 1125-1129. | 0.6 | 2 |
| 220 | The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 8489-8492. | 3.3 | 198 |
| 221 | Vaccination of Melanoma Patients with Interleukin 4 Gene-Transduced Allogeneic Melanoma Cells. <i>Human Gene Therapy</i> , 1999, 10, 2907-2916. | 1.4 | 61 |
| 222 | Dendritic Cells Infiltrating Tumors Cotransduced with Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf) and Cd40 Ligand Genes Take up and Present Endogenous Tumor-Associated Antigens, and Prime Naive Mice for a Cytotoxic T Lymphocyte Response. <i>Journal of Experimental Medicine</i> , 1999, 190, 125-134. | 4.2 | 168 |
| 223 | DNA vaccination against the ovarian carcinoma-associated antigen folate receptor $\hat{\pm}$ (FR $\hat{\pm}$) induces cytotoxic T lymphocyte and antibody responses in mice. <i>Cancer Gene Therapy</i> , 1999, 6, 349-357. | 2.2 | 17 |
| 224 | Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine. <i>Gene Therapy</i> , 1999, 6, 865-872. | 2.3 | 21 |
| 225 | Enforced expression of HOXB7 promotes hematopoietic stem cell proliferation and myeloid-restricted progenitor differentiation. <i>Oncogene</i> , 1999, 18, 1993-2001. | 2.6 | 54 |
| 226 | In vitro analysis of the melanoma/endothelium interaction increasing the release of soluble intercellular adhesion molecule 1 by endothelial cells. <i>Cancer Immunology, Immunotherapy</i> , 1999, 48, 132-138. | 2.0 | 8 |
| 227 | Salmonella vaccine carrier strains: effective delivery system to trigger anti-tumor immunity by oral route. <i>European Journal of Immunology</i> , 1999, 29, 693-699. | 1.6 | 56 |
| 228 | Interleukin-12 as an Adjuvant for Cancer Immunotherapy. <i>Methods</i> , 1999, 19, 114-120. | 1.9 | 60 |
| 229 | Interaction between endothelial cells and the secreted cytokine drives the fate of an IL4- or an IL5-transduced tumour. , 1998, 186, 390-397. | | 13 |
| 230 | Tumor and dendritic cells as cellular vaccines: confrontation and perspectives â€“ a symposium in writing. <i>Cancer Immunology, Immunotherapy</i> , 1998, 46, 69-69. | 2.0 | 2 |
| 231 | HIV/gp120 and PMA/ionomycin induced apoptosis but not activation induced cell death require PKC for Fas-L upregulation. <i>FEBS Letters</i> , 1998, 436, 461-465. | 1.3 | 11 |
| 232 | Transduction of the SkBr3 breast carcinoma cell line with the HOXB7 gene induces bFGF expression, increases cell proliferation and reduces growth factor dependence. <i>Oncogene</i> , 1998, 16, 3285-3289. | 2.6 | 78 |
| 233 | Interferon $\hat{\beta}$ -independent Rejection of Interleukin 12â€“transduced Carcinoma Cells Requires CD4+ T Cells and Granulocyte/Macrophage Colonyâ€“stimulating Factor. <i>Journal of Experimental Medicine</i> , 1998, 188, 133-143. | 4.2 | 54 |
| 234 | Interleukin 12â€“mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice. <i>Journal of Experimental Medicine</i> , 1998, 188, 589-596. | 4.2 | 291 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 235 | Gene Transfer in Dendritic Cells, Induced by Oral DNA Vaccination With Salmonellatyphimurium, Results in Protective Immunity Against a Murine Fibrosarcoma. <i>Blood</i> , 1998, 92, 3172-3176. | 0.6 | 173 |
| 236 | Gene Transfer in Dendritic Cells, Induced by Oral DNA Vaccination With Salmonellatyphimurium, Results in Protective Immunity Against a Murine Fibrosarcoma. <i>Blood</i> , 1998, 92, 3172-3176. | 0.6 | 32 |
| 237 | Antitumor Efficacy of Adenocarcinoma Cells Engineered to Produce Interleukin 12 (IL-12) or Other Cytokines Compared With Exogenous IL-12. <i>Journal of the National Cancer Institute</i> , 1997, 89, 1049-1058. | 3.0 | 158 |
| 238 | Cytokine Gene Transduction in the Immunotherapy of Cancer. <i>Advances in Pharmacology</i> , 1997, 40, 259-307. | 1.2 | 43 |
| 239 | Limited Efficacy of the HSV-TK/GCV System for Gene Therapy of Malignant Gliomas and Perspectives for the Combined Transduction of the Interleukin-4 Gene. <i>Human Gene Therapy</i> , 1997, 8, 1345-1353. | 1.4 | 69 |
| 240 | Apoptosis induced by HIV-gp120 in a Th1 clone involves the generation of reactive oxygen intermediates downstream CD95 triggering. <i>FEBS Letters</i> , 1997, 411, 87-92. | 1.3 | 13 |
| 241 | Differential Susceptibility to HIV-GP120â€“Sensitized Apoptosis in CD4+ T-Cell Clones With Different T-Helper Phenotypes: Role of CD95/CD95L Interactions. <i>Blood</i> , 1997, 89, 558-569. | 0.6 | 51 |
| 242 | Immunotherapy. I: Cytokine gene transfer strategies. , 1997, 16, 421-432. | | 22 |
| 243 | Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability. <i>Cancer Immunology, Immunotherapy</i> , 1997, 44, 197-203. | 2.0 | 67 |
| 244 | Cytokines, tumour-cell death and immunogenicity: a question of choice. <i>Trends in Immunology</i> , 1997, 18, 32-36. | 7.5 | 161 |
| 245 | The defined attenuated <i>Listeria monocytogenes</i> \hat{I}^{mpl2} mutant is an effective oral vaccine carrier to trigger a long-lasting immune response against a mouse fibrosarcoma. <i>European Journal of Immunology</i> , 1997, 27, 1570-1575. | 1.6 | 49 |
| 246 | Genetic modification of a carcinoma with the IL-4 gene increases the influx of dendritic cells relative to other cytokines. <i>European Journal of Immunology</i> , 1997, 27, 2375-2382. | 1.6 | 47 |
| 247 | B7.1 gene transduction of human renal-cell-carcinoma cell lines restores the proliferative response and cytotoxic function of allogeneic T cells. , 1996, 67, 769-776. | | 33 |
| 248 | IL-1 $\hat{\pm}$ gene-transfected human melanoma cells increase tumor-cell adhesion to endothelial cells and their retention in the lung of nude mice. , 1996, 67, 856-863. | | 34 |
| 249 | Immunotherapy I: Cyclosine gene transfer strategies. <i>Cancer and Metastasis Reviews</i> , 1996, 15, 317-328. | 2.7 | 24 |
| 250 | Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.. <i>Journal of Experimental Medicine</i> , 1996, 183, 317-322. | 4.2 | 516 |
| 251 | Limited Antitumor T Cell Response in Melanoma Patients Vaccinated with Interleukin-2 Gene-Transduced Allogeneic Melanoma Cells. <i>Human Gene Therapy</i> , 1996, 7, 1955-1963. | 1.4 | 83 |
| 252 | CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. <i>European Journal of Immunology</i> , 1995, 25, 137-146. | 1.6 | 120 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 253 | A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes. <i>European Journal of Immunology</i> , 1995, 25, 2737-2742. | 1.6 | 48 |
| 254 | Anin vivo model to compare human leukocyte infiltration in carcinoma xenografts producing different chemokines. <i>International Journal of Cancer</i> , 1995, 62, 572-578. | 2.3 | 29 |
| 255 | Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: Do animal studies really support clinical trials?. <i>Cancer Immunology, Immunotherapy</i> , 1995, 41, 265-270. | 2.0 | 20 |
| 256 | Redundancy of autocrine loops in human rhabdomyosarcoma cells: induction of differentiation by suramin. <i>British Journal of Cancer</i> , 1995, 72, 1224-1229. | 2.9 | 42 |
| 257 | IL-12 Inhibits Apoptosis Induced in a Human Th1 Clone by gp120/CD4 Cross-Linking and CD3/TCR Activation or by IL-2 Deprivation. <i>Cellular Immunology</i> , 1995, 161, 14-21. | 1.4 | 59 |
| 258 | A Human Melanoma Cell Line Transduced with an Interleukin-4 Gene by a Retroviral Vector Releases Biologically Active IL-4 and Maintains the Original Tumor Antigenic Phenotype. <i>Human Gene Therapy</i> , 1995, 6, 1427-1436. | 1.4 | 13 |
| 259 | Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: do animal studies really support clinical trials?. <i>Cancer Immunology, Immunotherapy</i> , 1995, 41, 265-270. | 2.0 | 2 |
| 260 | Interleukin-Gene-Transduced Human Melanoma Cells Efficiently Stimulate MHC-Unrestricted and MHC-Restricted Autologous Lymphocytes. <i>Human Gene Therapy</i> , 1994, 5, 1139-1150. | 1.4 | 44 |
| 261 | Refined localization of H7 and Ctt1 on distal mouse chromosome 9. <i>Immunogenetics</i> , 1994, 40, 79-81. | 1.2 | 5 |
| 262 | Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. <i>International Journal of Cancer</i> , 1994, 56, 853-857. | 2.3 | 222 |
| 263 | Expression of a growth arrest specific gene (gas-6) during liver regeneration: Molecular mechanisms and signalling pathways. <i>Journal of Cellular Physiology</i> , 1994, 158, 263-269. | 2.0 | 7 |
| 264 | Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now?. <i>Trends in Immunology</i> , 1994, 15, 48-51. | 7.5 | 255 |
| 265 | In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5. <i>International Journal of Cancer</i> , 1993, 54, 8-15. | 2.3 | 68 |
| 266 | Immunodominance in the T-cell response to multiple non-H-2 histocompatibility antigens. V. Chromosomal mapping of the immunodominant cytotoxic T-cell target-1 (CTT-1). <i>Immunogenetics</i> , 1993, 38, 157-60. | 1.2 | 6 |
| 267 | Lymphotoxin gene expression by melanocytes and melanoma cell lines and persistence of unspliced mRNA. <i>FEBS Letters</i> , 1993, 335, 114-118. | 1.3 | 8 |
| 268 | The Role of Cytokines in Antitumor Immune Response: From Detection to Gene Therapy. <i>ImmunoMethods</i> , 1993, 3, 34-42. | 0.8 | 0 |
| 269 | Sequence of human GAS3/PM22 full-length cDNA. <i>Gene</i> , 1993, 126, 289-290. | 1.0 | 10 |
| 270 | Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma.. <i>Journal of Experimental Medicine</i> , 1993, 178, 151-161. | 4.2 | 171 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 271 | Cytokine-Induced Tumor Immunogenicity: From Exogenous Cytokines to Gene Therapy. <i>Journal of Immunotherapy</i> , 1993, 14, 253-257. | 1.2 | 24 |
| 272 | Isolation and mapping to 17p12-13 of the human homologous of the murine growth arrest specific Gas-3 gene. <i>Human Molecular Genetics</i> , 1992, 1, 331-334. | 1.4 | 11 |
| 273 | Expression of cytokine genes, including IL-6, in human malignant melanoma cell lines. <i>Melanoma Research</i> , 1992, 2, 181-190. | 0.6 | 84 |
| 274 | Evaluation of osteonectin as a diagnostic marker of osteogenic bone tumors. <i>Human Pathology</i> , 1992, 23, 1326-1331. | 1.1 | 36 |
| 275 | Localization of growth arrest-specific genes on mouse Chromosomes 1, 7, 8, 11, 13, and 16. <i>Mammalian Genome</i> , 1992, 2, 130-134. | 1.0 | 36 |
| 276 | Expression of a growth arrest specific gene (gas-1) in transformed cells. <i>British Journal of Cancer</i> , 1992, 66, 27-31. | 2.9 | 4 |
| 277 | Cytokine gene transfer in tumor cells as an approach to antitumor therapy. <i>International Journal of Clinical and Laboratory Research</i> , 1992, 21, 278-282. | 1.0 | 4 |
| 278 | Multiple molecular alterations in mouse lung tumors. <i>Molecular Carcinogenesis</i> , 1992, 5, 155-160. | 1.3 | 59 |
| 279 | Down-regulation of SPARC/Osteonectin/BM-40 expression in methylcholanthrene-induced fibrosarcomas and in kirsten-MSV transformed fibroblasts. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, 58-62. | 0.9 | 11 |
| 280 | Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. <i>Journal of Experimental Medicine</i> , 1991, 173, 889-897. | 4.2 | 304 |
| 281 | Tumor-cell-targeted cytokine gene therapy. <i>Trends in Immunology</i> , 1991, 12, 249-250. | 7.5 | 5 |
| 282 | The high lysability by lak cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less-differentiated phenotype. <i>International Journal of Cancer</i> , 1991, 47, 746-754. | 2.3 | 52 |
| 283 | Modulation of multidrug resistance by verapamil or mdr1 anti-sense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killers in mdr-resistant human carcinoma (LoVo) line. <i>International Journal of Cancer</i> , 1990, 46, 727-732. | 2.3 | 55 |
| 284 | Effect of adrenergic and Ca ²⁺ antagonists on increased ornithine decarboxylase expression in regenerating rat liver. <i>Biochemical Pharmacology</i> , 1990, 40, 1605-1613. | 2.0 | 11 |
| 285 | A TaqI RFLP at the gas-2 locus. <i>Nucleic Acids Research</i> , 1989, 17, 7545-7545. | 6.5 | 0 |
| 286 | Ava I RFLP at the gas-1 locus on mouse chromosome 12. <i>Nucleic Acids Research</i> , 1989, 17, 5415-5415. | 6.5 | 3 |
| 287 | Strain polymorphism and tentative mapping of mouse ornithine decarboxylase. <i>Nucleic Acids Research</i> , 1988, 16, 9075-9075. | 6.5 | 2 |
| 288 | Inheritance of a mutant histocompatibility gene and a new mammary tumor virus genome in the B6.KH-84 mouse strain. <i>Immunogenetics</i> , 1987, 26, 99-104. | 1.2 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 289 | Treatment of a low immunogenic experimental tumour with alloactivated or tumour-immune lymphocytes. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 1987, 907, 163-174. | 3.3 | 3 |
| 290 | Control of human melanoma growth in nude mice by autologous allo-activated peripheral blood lymphocytes. <i>International Journal of Cancer</i> , 1986, 38, 923-927. | 2.3 | 2 |
| 291 | Adoptive immunotherapy of cancer with immune and activated lymphocytes: Experimental and clinical studies. <i>Research in Clinic and Laboratory</i> , 1986, 16, 1-20. | 0.3 | 7 |
| 292 | Adoptive immunotherapy of a BALB/c lymphoma by syngeneic anti-DBA/2 immune lymphoid cells: Characterization of the effector population and evidence for the role of the host's non-T cells. <i>Cancer Immunology, Immunotherapy</i> , 1985, 20, 198-204. | 2.0 | 10 |
| 293 | Genetic Unresponsiveness to a Murine Fibrosarcoma Determined by the Host Genetic Environment but not by Lymphocyte Precursor Genotype. <i>Tumori</i> , 1985, 71, 91-96. | 0.6 | 0 |
| 294 | Passive adoptive immunotherapy of low-immunogenic BALB/C lymphoma by syngeneic alloimmune T lymphocytes. <i>International Journal of Cancer</i> , 1984, 34, 807-813. | 2.3 | 12 |
| 295 | In vitro detection of cell-mediated immunity to individual tumor-specific antigens of chemically induced BALB/c fibrosarcomas. <i>International Journal of Cancer</i> , 1983, 31, 483-489. | 2.3 | 22 |
| 296 | Cross-reactions between tumor cells and allogeneic normal tissues. inhibition of a syngeneic lymphoma outgrowth in h-2 and non-h-2 alloimmune balb/c mice. <i>International Journal of Cancer</i> , 1982, 29, 323-332. | 2.3 | 26 |